Investing

7 Speculative Analyst Stocks Called to Rise 100% or More

Jon C. Ogg

Fusion Telecommunications International Inc. (NASDAQ: FSNN) was started with a Buy rating at B. Riley on April 26. The firm assigned a $3 price target, implying more than 100% upside from the $1.43 prior closing price, with a market cap of only about $35 million. Fusion Telecom shares ended April at $1.61, in a 52-week range of $0.96 to $2.46.

This analyst call came on the heels of the company announcing it secured $2.1 million over five years to provide single-source cloud solutions to a leading Midwestern and Southeastern health system.

Quotient Ltd. (NASDAQ: QTNT) was started as Buy at BTIG Research on April 18, and it was assigned a $22 price target, which compares to a $6.28 prior closing price. BTIG did participate in underwriting a securities offering shortly before this maker of diagnostics testing for blood grouping and serological disease screening was given such a big upside call. Quotient was indicated up 11% at $6.95 at the time, due to the massive upside price target, and it closed out April at $6.81. Quotient has a 52-week range of $3.75 to $12.96 and a market cap of about $250 million.

Superconductor Technologies Inc. (NASDAQ: SCON) was raised to Buy from Neutral at Rodman & Renshaw on April 6, but the price target of $3 represented more than 100% from the $1.46 prior closing price. This stock was initially up 17% at $1.72 at one point on the day the big upside call was made, and it ended April at $1.69 a share, with a market cap of just about $16 million or so. The 52-week range is $1.04 to $4.50.

Superconductor Tech makes high-temperature superconductor wires using the Conductus HTS wire products for superconducting high-power transmission cables. It has a history of losing money and hardly generates any real revenues at this time, but that may change quite soon. The firm feels that Superconductor Tech has passed multiple hurdles and that it can now maintain structural integrity while meeting the critical current carrying capacity requirement.

Synacor Inc. (NASDAQ: SYNC) was started with a Buy rating at Canaccord Genuity on April 18. While this was after a secondary offering that the firm was involved in earlier in April, the $8 price target represented more than 100% in implied upside to the $3.55 previous closing price.

Upcoming growth was cited by Canaccord Genuity for a future rerating of this growth company in that call. Synacor has a 52-week range of $1.35 to $4.25 and very limited analyst coverage. The market cap is about $130 million. The month-end share price in April was $3.55.

TG Therapeutics Inc. (NASDAQ: TGTX) was started with a Buy rating and assigned a $23 price target at Jefferies on April 25. This represented more than 100% upside, given the $10.40 prior closing price. TG Therapeutics ended last month at $11.06, in a 52-week range is $4.10 to $15.05. Its market cap is about $620 million.

The firm felt that TG Therapeutics is undervalued, based on the long-term promise of ublituximab, TGR-1202, and TG-1303 (ubli + 1202) in B-cell cancers and multiple sclerosis. Jefferies even believes an FDA precedent exists for accelerated approval based on objective response rate.

TherapeuticsMD Inc. (NYSEMKT: TXMD) saw one of the calls that investors are often leery of: a big price drop but the analyst remains unphased with a massive target. Jefferies reiterated its Buy rating on TherapeuticsMD on April 11 with an $18 price target. This was right after it received an FDA letter about deficiencies in its treatment of moderate to severe dysparaeunia. Jefferies sees this not being a death sentence and did not back away from its upside target.

The stock’s $6.20 prior closing price was continued lower over the course of the month, with TherapeuticsMD closing out April at $5.10, with a $1 billion market cap and a 52-week range of $4.39 to $9.29.